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Abstract
Various dietary antioxidants, including vitamins, flavonoids, curcumin, and a coumarin, were
conjugated with paclitaxel (1) through an ester linkage. The newly synthesized compounds were
evaluated for cytotoxic activity against several human tumor cell lines as well as the corresponding
normal cell lines. Interestingly, most tested conjugates selectively inhibited the growth of 1A9
(ovarian) and KB (nasopharyngeal) tumor cells without activity against other cell lines. Particularly,
conjugates 16 and 20 were highly active against 1A9 (ED50 value of 0.005 μg/mL) as well as KB
(ED50 values of 0.005 and 0.14 μg/mL, respectively) cells. Compound 22b, the glycinate ester salt
of vitamin E conjugated with 1, appears to be a promising lead for further development as a clinical
trial candidate as it exhibited strong inhibitory activity against Panc-1 (pancreatic cancer) with less
effect on the related E6E7 (normal) cell line.
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In current cancer therapy, undesirable side effects due to toxicity of antitumor drugs on normal
tissues present an important problem to be solved. Therefore, a challenging research focus in
cancer treatment is the discovery of efficient antitumor drugs with high therapeutic indexes,
which will have selective activity against target tumors and reduced normal tissue damage.
Among various strategies to improve drug selectivity, conjugation of cytotoxic drug
components has proven to be a promising approach to enhance the activity as well as selectivity
of an individual lead compound.1 This concept is now accepted as an effective strategy for
designing ligands, inhibitors, and other drugs that influence biological systems.2 On the basis
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of this theory, some interesting results have been reported by our group3 as well as others4 in
recent years. In our prior study, we explored the syntheses and evaluation of heterodimer
conjugates, which combined two kinds of antitumor drugs through various linkages, as novel
antitumor agents.5
Dietary anti-oxidants, such as flavonoids and vitamins A, C, and E that are found in various
foods, can act as cancer preventive agents. These compounds are capable of neutralizing and
deactivating reactive oxygen species, which can seriously damage DNA and other cellular
molecules, thereby causing tumors.6 Antioxidants act not only as cancer preventive agents,
but also as therapeutic biologic response modifiers, and are able to directly induce apoptosis
in established tumor cells. In addition, evidence shows that antioxidants can enhance
chemotherapeutic antitumor effects.7
Therefore, conjugation of antitumor drugs with dietary antioxidants might provide new classes
of antitumor drug candidates with tumor selectivity or activity against multi-drug resistant
cancer cell lines. We chose paclitaxel (1)8 as the antitumor base compound and various
antioxidants as the conjugate partners as shown in Figure 1. Vitamins,6 such as retinol (vitamin
A, 2a)9,10 and α–tocopherol (vitamin E, 3),9,11 are well known dietary antioxidants.
Compound 4 was also selected as a related vitamin E analog. Other known antioxidant agents,
including curcumin (5)6,12 found in turmeric, dehydrozingerone (6)13 isolated from ginger,
and its analog 7, were also used. In addition, antioxidant flavonoids6,14 and coumarins6,15
are widely found in various vegetables, fruits, nuts, coffee, tea or wine, and representative
compounds [galangin (8), chrysin (9), and 4-methylumbelliferone (10), respectively] were
conjugated with 1.
Paclitaxel (1) was reacted first with succinic anhydride in pyridine to give 11,16 which has a
succinate ester at the C-2′ position. However, esterification of 11 with 2a provided an unstable
compound; therefore, retinoic acid (2b, vitamin A acid) was reacted directly with 1 to afford
12. Conjugations of 11 with other antioxidants, 3–10, were carried out by a common
esterification method using EDCI in the presence of DMAP to give 13–20. Water solubility,
which is connected with oral bioavailability, is always of concern for drug discovery and
development. Accordingly, the resulting conjugates, 12–14 and 16–18, were converted to the
corresponding glycinate esters, 21–26. These esters can be converted to various salts. As
discussed later, the paclitaxel-vitamin E conjugate (13) showed good activity against a
pancreatic cancer cell line with less effect against the related normal cell line. Therefore, in
order to increase water-solubility, conjugate 13 was converted first to various amine (22, 27,
and 28) or carboxylic (29) esters and then to the corresponding hydrochloride (22a, 27a,
28a), methanesulfonate (22b, 28b), or triethylammonium (29a) salts as shown in Scheme 2.
The newly obtained conjugates were evaluated for cytotoxic activity against several human
tumor cell lines. Interestingly, conjugates 12, 14, and 16–20 and the glycinate esters 21 and
23–26 selectively inhibited the growth of 1A9 and KB cells (data shown in Table 1), without
inhibition of the remaining cell lines [lung carcinoma (A549), breast cancer (MCF-7), prostate
carcinoma (LN-CAP, PC-3, DU-145) and multi-drug resistant variant expressing P-
glycoprotein KB-VIN]. Conjugates 16 (paclitaxel-dehydrozingerone) and 20 (paclitaxel-
coumarin) exhibited the highest potency against these two cell lines (1A9: ED50 0.005 μg/mL;
KB: ED50 0.005 and 0.14 μg/mL, respectively). Moreover, against KB cells, glycinate ester
26 showed significantly increased cytotoxic activity (ED50 0.09 μg/mL) compared to the
related parent compound 18 (ED50 0.26 μg/mL), even though glycinate esters 23-25 showed
similar or lower activity compared with the parent compounds 14, 16, and 17.
Conjugate 13, its C-7 esters 22 and 27–29, their corresponding salts, and conjugate 15 were
evaluated for cytotoxic activity against A549, 1A9, colon adenocarcinoma (HCT-8),
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epidermoid skin carcinoma (A431), KB, and KB-VIN cell lines. The data are shown in Table
2. The ED50 values of 1, 3 or 5, and a 1:1 mixture of 1 with 3 or 5 are also shown for comparison.
The 1:1 mixtures of 1 with 3 or 5 showed similar results to 1 itself against A549, A431 and
1A9 cells but were less potent against HCT-8 cells. However, the related conjugates 13 and
15 showed unique selectivity. Vitamin E conjugate 13 lost cytotoxic activity against most cell
lines, and inhibited the growth of only the A431 cell line with an ED50 value of 0.1 μg/mL. In
comparison, curcumin conjugate 15 showed similar potencies to 1 against A549, 1A9, A431,
KB and KB-VIN cells, but lost activity against HCT-8 cells. Among the C-7 esters/salts of
conjugate 13 (22 and 27–29), only the glycinate ester 22, succinic ester 29, and their salts
displayed cytotoxic activity against the A431 cell line with similar ED50 values to the parent
compound 13.
Conjugate 13 and its related esters/salts were also screened against multiple human tumor as
well as the corresponding normal cell lines. Figure 2 shows selected data after 48 h. Conjugate
13 demonstrated less growth inhibition of normal pancreatic cells (E6E7) than related tumor
cells (Panc-1), whereas growths of other normal cells were inhibited more or as strongly than
the related tumor cells. Glycinate ester salt 22b also showed less inhibition of E6E7 growth
and the highest potency against Panc-1, compared with the other esters/salts,
In conclusion, we have synthesized various 1-antioxidant conjugates linked through an ester
bond at the 2′-position of 1. All conjugates were screened against various tumor cell lines and
showed tumor-selective activity. Most conjugates selectively inhibited the growth of 1A9 and
KB tumor cells and lacked activity against other tested cell lines. On the other hand, conjugate
13 showed cytotoxic activity only against A431, while conjugate 17 lacked any activity against
HCT-8 while retaining similar activity to 1 against the other tumor cell lines. Salt 22b exhibited
inhibitory activity against Panc-1 with less effect on the related normal cell. Compound 22b
appears to be a promising new lead for further development into a clinical trial candidate. In
summary, the conjugation of 1 with dietary antioxidants enhanced tumor selectivity dependant
on the identity of the partner compound.
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Liver human hepatomacarcinoma (SKHep), normal liver epithelial cell (Chang Liv), human
ovarian carcinoma (2774), normal surface ovarian epithelial cell (IOSE), human pancreatic
cancer cell (Panc 1), normal ovarian epithelial cell (E6E7), human lung cancer cell (H1299),
normal human fibroblast (W138), breast cancer (MCF-7) and normal breast epithelial cell
(MCF-10A).
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Table 1
Cytotoxic activity data for taxol conjugates 12, 14, 16–21, 23–26 [ED50 (μg/mL)]a,b
Cell Line Cell Line
Conjugate 1A9c KBc Glycinate Ester 1A9 KB
12 0.49 0.20 21 4.47 7.65
14 0.20 0.94 23 1.01 9.79
16 0.005 0.005 24 0.63 0.70
17 0.14 0.39 25 0.19 0.34






Cytotoxicity as ED50 values for each cell line, the concentration of compound that caused 50% reduction in absorbance at 562 nm relative to untreated
cells using the sulforhodamine B assay.
b
All compounds tested did not reach 50% inhibition against human lung carcinoma (A549), breast cancer (MCF-7), human prostate carcinoma (LN-CAP,
PC-3, DU-145), and multi-drug resistant KB variant expressing P-glycoprotein (KB-VIN).
c
Human ovarian carcinoma (1A9), human epidermoid carcinoma of the nasopharynx (KB).
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